KR102509579B1 - Oral composition comprising cassava extract - Google Patents
Oral composition comprising cassava extract Download PDFInfo
- Publication number
- KR102509579B1 KR102509579B1 KR1020150136505A KR20150136505A KR102509579B1 KR 102509579 B1 KR102509579 B1 KR 102509579B1 KR 1020150136505 A KR1020150136505 A KR 1020150136505A KR 20150136505 A KR20150136505 A KR 20150136505A KR 102509579 B1 KR102509579 B1 KR 102509579B1
- Authority
- KR
- South Korea
- Prior art keywords
- oral
- streptococcus
- cassava
- extract
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 239000000284 extract Substances 0.000 title claims abstract description 39
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 title claims abstract description 37
- 241000658379 Manihot esculenta subsp. esculenta Species 0.000 title 1
- 240000003183 Manihot esculenta Species 0.000 claims abstract description 37
- 208000025157 Oral disease Diseases 0.000 claims abstract description 19
- 208000030194 mouth disease Diseases 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 206010006326 Breath odour Diseases 0.000 claims description 17
- 208000002925 dental caries Diseases 0.000 claims description 16
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
- 239000000606 toothpaste Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 241000605894 Porphyromonas Species 0.000 claims description 12
- 229940034610 toothpaste Drugs 0.000 claims description 12
- 210000005239 tubule Anatomy 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 241000605862 Porphyromonas gingivalis Species 0.000 claims description 10
- 241000194017 Streptococcus Species 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 241000194019 Streptococcus mutans Species 0.000 claims description 9
- -1 oral ointment Substances 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 239000013588 oral product Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 241000194023 Streptococcus sanguinis Species 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000002324 mouth wash Substances 0.000 claims description 6
- 229940023486 oral product Drugs 0.000 claims description 6
- 208000032139 Halitosis Diseases 0.000 claims description 5
- 229940051866 mouthwash Drugs 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- 241000194024 Streptococcus salivarius Species 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical group O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims description 2
- 229940042125 oral ointment Drugs 0.000 claims description 2
- 229940041678 oral spray Drugs 0.000 claims description 2
- 239000000668 oral spray Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 210000000214 mouth Anatomy 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 4
- 229930014626 natural product Natural products 0.000 abstract description 2
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 208000028169 periodontal disease Diseases 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 210000004268 dentin Anatomy 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 210000003298 dental enamel Anatomy 0.000 description 4
- 239000004088 foaming agent Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 208000007565 gingivitis Diseases 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 201000001245 periodontitis Diseases 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000011775 sodium fluoride Substances 0.000 description 4
- 235000013024 sodium fluoride Nutrition 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- CSAVDNHVPJNKTC-UHFFFAOYSA-N 5-methyl-2-propan-2-ylcyclohexan-1-ol;5-methyl-2-propan-2-ylphenol;2,2,4-trimethyl-3-oxabicyclo[2.2.2]octane Chemical compound CC(C)C1CCC(C)CC1O.CC(C)C1=CC=C(C)C=C1O.C1CC2CCC1(C)OC2(C)C CSAVDNHVPJNKTC-UHFFFAOYSA-N 0.000 description 3
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960003260 chlorhexidine Drugs 0.000 description 3
- 238000000586 desensitisation Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940076522 listerine Drugs 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 3
- 235000019204 saccharin Nutrition 0.000 description 3
- 229940081974 saccharin Drugs 0.000 description 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 229960004418 trolamine Drugs 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 2
- 206010033102 Otosalpingitis Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000003074 dental pulp Anatomy 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 229940091249 fluoride supplement Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 208000024386 fungal infectious disease Diseases 0.000 description 2
- 229940029982 garlic powder Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229940084560 sanguinarine Drugs 0.000 description 2
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 235000004456 Manihot esculenta Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 208000002595 Radicular cyst Diseases 0.000 description 1
- ITJLNEXJUADEMK-UHFFFAOYSA-N Shirin Natural products CCC(C)(O)c1c(Cl)c(OC)c(C)c2OC(=O)c3c(C)c(Cl)c(O)c(Cl)c3Oc12 ITJLNEXJUADEMK-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000037123 dental health Effects 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 229940111685 dibasic potassium phosphate Drugs 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 201000005128 suppurative periapical periodontitis Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YUOWTJMRMWQJDA-UHFFFAOYSA-J tin(iv) fluoride Chemical compound [F-].[F-].[F-].[F-].[Sn+4] YUOWTJMRMWQJDA-UHFFFAOYSA-J 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000012711 vitamin K3 Nutrition 0.000 description 1
- 239000011652 vitamin K3 Substances 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 구강질환 예방 또는 치료용 조성물에 관한 것으로, 보다 상세하게는 카사바 추출물을 유효성분으로 포함하는 구강용 조성물에 관한 것이다. 본 발명의 카사바 추출물을 포함하는 구강용 조성물은 구강질환 예방 또는 치료 효과가 우수하며, 천연물 유래의 물질이어서 독성이 없으며, 인체에 적용하여도 부작용을 유발하지 않아 활용도가 높다.The present invention relates to a composition for preventing or treating oral diseases, and more particularly, to a composition for oral cavity containing a cassava extract as an active ingredient. The oral composition containing the cassava extract of the present invention is excellent in preventing or treating oral diseases, is non-toxic because it is a material derived from natural products, and has high utilization because it does not cause side effects even when applied to the human body.
Description
본 발명은 구강용 조성물에 관한 것으로, 보다 상세하게는 구강질환 예방 또는 치료용 구강용 조성물에 관한 것이다.The present invention relates to a composition for oral cavity, and more particularly, to a composition for oral cavity for preventing or treating oral diseases.
치아건강의 개념이 사회생활개념으로 변화되면서 구강건강에 관한 관심이 증대되고 있으며 구강질환의 예방과 치료뿐만 아니라, 사회생활을 하는데 있어서 중요한 대인관계의 장애가 되는 구취에 대한 관심도 높아지고 있는 실정이다.As the concept of dental health changes to the concept of social life, interest in oral health is increasing, and interest in bad breath, which is an important interpersonal obstacle in social life as well as prevention and treatment of oral diseases, is also increasing.
치아조직은 에나멜질, 시멘트질 및 상아질로 구성되어 있다. 외부에 노출되어 있는 치아의 바깥쪽은 에나멜질로 덮여 있고, 치조골 내에 위치하는 치아 뿌리 부분의 바깥쪽은 시멘트질로 덮여 있으며, 이들 내부에 상아질이 존재한다. 상아질에는 상아세관이라는 미세한 관이 상아질 전체에 걸쳐 분포하고 있다. Tooth tissue is composed of enamel, cementum and dentin. The outside of the tooth exposed to the outside is covered with enamel, the outside of the tooth root portion located in the alveolar bone is covered with cementum, and dentin exists inside them. In dentin, fine tubes called dentinal tubules are distributed throughout the dentin.
치아의 시린이 증상은 노출된 치아의 상아질 부분이 찬 공기나 자극적인 음식물 등에 접촉되었을 때 민감하게 느껴지는 것으로서, 이 증상의 근본적인 원인으로서 치아의 상아질에 존재하는 많은 세관이 외부로 노출되면서 나타난다. 치아의 시린이 증상은 가벼운 증상에서 격렬하고 지속적인 통증까지 다양하게 나타날 수 있다. 또한, 치아는 특성상 재생이 되지 않기 때문에 진통제나 소염제 등의 복용은 시린 현상의 근본적인 해결책이 되지 못하므로 시린이 증상을 완화하기 위한 여러 치료법이 발달하였다.Tooth ache symptoms are sensitive when the exposed dentin part of the tooth comes into contact with cold air or irritating food. Toothache symptoms can range from mild symptoms to intense and persistent pain. In addition, since teeth do not regenerate by nature, taking painkillers or anti-inflammatory drugs is not a fundamental solution to the ache, so various treatments have been developed to alleviate the symptoms of ache.
시린이 증상의 치료는 크게 상아세관 밀봉법과 치수신경 탈감작법 두가지가 있다. 상아세관 밀봉법은 노출된 상아세관을 레진 등으로 메우거나 불소 도포 등으로 손실된 법랑질을 다시 회복하는 방법이고, 치수신경 탈감작법은 신경전달이 나트륨 이온과 칼륨 이온의 적정 비율에 의해 조절되는 점을 감안하여 칼륨 이온의 함량을 인위적으로 높여줌으로써 신경이 시린 통증을 느끼지 못하게 하는 치료법이다. 그러나 이러한 전문 치료법의 시술은 치과에 가서 받아야 하는 번거로움이 있어 평소 생활에서 시린이를 치료 또는 예방할 수 있는 시린이를 위한 치약들이 판매되고 있다.There are two main treatments for syringitis: dentinal tubule sealing and pulpal nerve desensitization. Dentinal tubule sealing method is a method to restore enamel lost by filling exposed dentinal tubules with resin or applying fluoride, etc., and pulp nerve desensitization method is that neurotransmission is controlled by an appropriate ratio of sodium ions and potassium ions. It is a treatment that prevents the nerves from feeling the pain by artificially increasing the content of potassium ions in consideration of However, these professional treatment procedures are cumbersome to go to the dentist, so toothpastes for cold teeth that can treat or prevent cold teeth in everyday life are sold.
이러한 치약들은 상기 2가지 치료방법에 유용한 유효성분을 함유하고 있다. 그러나 이 중 제이인산칼륨 성분 등을 함유하여 치수신경 탈감작 효능이 나타나도록 구성된 치약은 효능이 나타나는 시간이 15일 정도로 길기 때문에 상대적으로 효능이 빨리 나타나는 상아세관 밀봉법에 의한 효능을 갖는 치약이 선호되고 있다. These dentifrices contain active ingredients useful for the above two treatment methods. However, among these, toothpaste containing dibasic potassium phosphate component to exhibit pulpal nerve desensitization effect takes as long as 15 days, so toothpaste with efficacy by dentinal tubule sealing method, which shows efficacy relatively quickly, is preferred. there is.
그러나 종래의 상아세관 밀봉효과를 활용한 시린이 전문 치약의 경우 상아세관을 밀봉하기 위하여 유효성분의 미세한 파우더를 함유하게 되는데 통상적으로 칫솔질하는 과정에서 금방 묽게 희석되고, 물로 헹구는 과정에서 대부분 씻겨나가는 바람에 세관이 밀봉되지 못하고 다시 노출하게 되는 문제점이 있었다.However, in the case of a toothpaste specializing in toothpaste that utilizes the conventional dentinal tubule sealing effect, it contains fine powder of active ingredients to seal the dentinal tubules. There was a problem that the customs could not be sealed and exposed again.
한편, 구취의 원인은 크게 구강 내 원인, 구강 외 원인, 심인적 원인으로 분류되고 그 중 구취 원인의 80~90% 정도를 차지하는 구강 내 원인으로 타액량 감소, 타액 점조도 증가, 수소이온농도 완충능력 감소, 구강 미생물의 양과 활동성 증가 및 혀의 배면에 부착된 설태와 치료되지 않은 치아 우식증과 치주질환과 같은 구강질환 등이 있다.On the other hand, the causes of halitosis are largely classified into oral, extraoral, and psychogenic causes. Among them, oral causes account for 80 to 90% of the causes of bad breath. decrease in the amount and activity of oral microbes and oral diseases such as tongue plaque attached to the dorsal surface of the tongue and untreated dental caries and periodontal disease.
한편, 구강질환 중 치아 우식증과 치주질환은 통증, 저작기능 장애, 치주조직의 파괴 및 구취와 같은 다양한 임상적인 증상을 유발하고 치아상실을 초래하는 주된 요인으로 알려져 있으며 식생활의 변화로 치아 우식의 원인요소는 더 증가하고 있는 실정이다.On the other hand, among oral diseases, dental caries and periodontal disease cause various clinical symptoms such as pain, masticatory dysfunction, destruction of periodontal tissue and bad breath, and are known to be the main factors that cause tooth loss, and changes in dietary life are the cause of dental caries. elements are on the rise.
치면세균막 내에 서식하면서 치아우식, 치주질환 및 구취를 유발하는 구강병원균 증식을 억제하는 방법으로, 이들 세균들에 대한 살균 및 정균작용을 갖는 항생제를 포함한 다양한 종류의 항균제제가 충치, 치주질환, 치수 및 치근단 감염의 억제 및 치료제로써 개발되어 왔다. It is a method of inhibiting the growth of oral pathogens that live in dental bacterial film and cause dental caries, periodontal disease, and bad breath. It has been developed as an inhibitor and treatment agent for apical infection.
그런데, 항생제는 우리 몸에 대한 전신적인 부작용과 함께 구강 내 내성균의 출현 및 균교대증을 유발할 수 있기 때문에 장기적인 사용이 곤란하여 단지 치료제로만으로 이용될 수 있다는 단점이 있다. 또한, 항균제인 불소의 경우는 충치예방효과는 뚜렷하지만 아직까지 치주나 치수, 치근단 질환에 대한 효과는 보고된 바가 없다. 그 외에 치약, 양치액, 기타 구강청정제에 사용되고 있는 항균제제로는 생귀나린(sanguinarine), 리스테린(listerine), 퍼록사이드(peroxide), 클로르헥시딘(chlorhexidine) 등이 있는데, 생귀나린은 구강 내에서 세균에 대한 효과가 불분명하고 치주질환 치료효과에 대해서는 더욱 불분명할 뿐만 아니라 가격도 비싸다는 단점이 있고, 리스테린은 알코올이 주성분으로 실제 구강 내에서는 일시적인 효과 내지는 약간의 정균작용이 있으나 장기간 사용시 조직에 대해 위해작용도 나타날 수 있는 단점이 있으며, 최근 미백효과를 위해 첨가되고 있는 퍼록사이드는 세균에 대한 독성 작용이 있으나 동시에 인체조직에도 독성 작용을 나타내어 안전성에 문제가 있을 뿐 아니라 간혹 세균에서 퍼록사이드에 대한 내성균이 출현하기도 한다. 또한 클로르헥시딘은 치태형성억제와 더불어 치주질환 예방 및 치료제로써 현재까지 알려진 제제 중에서 가장 우수한 것으로 알려져 있으나, 조직에 대한 자극, 조직의 착색 및 변성, 특히 자극적인 맛이 강하고 냄새가 심한 부작용을 나타내는 문제점이 있을 뿐 아니라, 그 외도 균교대증이 유발될 수 있고, 발암성이 있어 임신부의 경우 사용이 제한되는 등 치료나 특히 예방의 목적으로 장기간 사용할 수 없는 단점이 있다(Contemporary periodontics [ed. R.J. Genco et al.], p161∼169, p368∼369, p433, C.V. Mosby Company, St. Louis, 1990).However, since antibiotics can cause the appearance of resistant bacteria in the oral cavity and mycosis, along with systemic side effects on our body, long-term use is difficult and can only be used as a therapeutic agent. In addition, in the case of fluoride, which is an antibacterial agent, the effect of preventing caries is clear, but no effect on periodontal, dental pulp, or apical diseases has been reported yet. In addition, antibacterial agents used in toothpaste, mouthwash, and other mouthwashes include sanguinarine, listerine, peroxide, and chlorhexidine. Sanguinarine is effective against bacteria in the oral cavity. Listerine has the disadvantage of being unclear and the effect of treating periodontal disease is not only unclear, but also expensive. Listerine has alcohol as its main component and has a temporary effect or a slight bacteriostatic effect in the oral cavity. Peroxide, which has recently been added for whitening effect, has a toxic effect on bacteria, but at the same time it also exhibits a toxic effect on human tissues, causing safety problems and sometimes bacteria resistant to peroxide may appear in bacteria. do. In addition, chlorhexidine is known to be the best among the agents known to date as a preventive and therapeutic agent for periodontal disease as well as to inhibit plaque formation. In addition, there are disadvantages in that it cannot be used for a long period of time for the purpose of treatment or prevention, such as that it can cause mycosis and is carcinogenic, limiting its use in pregnant women (Contemporary periodontics [ed. R.J. Genco et al. al.], p161-169, p368-369, p433, C.V. Mosby Company, St. Louis, 1990).
이에 따라, 본 발명자들은 상기와 같은 부작용에 대한 우려가 없으면서도 구강질환, 즉 치아우식, 치주질환, 구취, 시린이 등의 예방 및 개선에 효과가 뛰어난 천연소재를 도출하기 위해 연구를 수행하였다.Accordingly, the present inventors have conducted research to derive natural materials that are effective in preventing and improving oral diseases, such as dental caries, periodontal diseases, halitosis, and ache, without worrying about the side effects as described above.
이에 본 발명자들은 카사바 추출물이 구강질환에 우수한 효과를 갖는다는 사실을 확인함으로써 본 발명을 완성하였다.Accordingly, the present inventors completed the present invention by confirming that the cassava extract has an excellent effect on oral diseases.
따라서, 본 발명의 목적은 카사바(cassava) 추출물을 유효성분으로 포함하는 구강용 조성물을 제공하는 것이다.Accordingly, an object of the present invention is to provide a composition for oral use comprising a cassava extract as an active ingredient.
또한, 본 발명의 목적은 상기 조성물을 포함하는 구강용 제품을 제공하는 것이다.Another object of the present invention is to provide an oral product comprising the composition.
상기 과제를 해결하기 위한 하나의 구현예로서, 본 발명은 카사바(cassava, Manihot esculenta) 추출물을 유효성분으로 포함하는 구강용 조성물을 제공한다.As one embodiment for solving the above problems, the present invention provides an oral composition comprising a cassava ( Manihot esculenta ) extract as an active ingredient.
본 발명에서 상기 조성물은 구강질환 예방 또는 치료용일 수 있다.In the present invention, the composition may be used for preventing or treating oral diseases.
본 발명에서 상기 구강질환은 예를 들어, 이에 한정되는 것은 아니지만, 구취, 시린이, 치아 우식증, 치은염, 치주염, 구강 내 점막 궤양 및 치근단 질환 등을 포함하는 포괄적 개념이다.In the present invention, the oral disease is a comprehensive concept including, but not limited to, bad breath, tooth decay, dental caries, gingivitis, periodontitis, mucosal ulcers in the oral cavity, and apical diseases.
본 발명에서 상기 구강질환은 바람직하게는 시린이일 수 있다.In the present invention, the oral disease may preferably be syringi.
본 명세서에서 사용된 용어, "예방"은 상기 구강용 조성물을 이용하여 질환을 억제 또는 지연시키는 모든 행위를 의미한다. 또한, 본 명세서에서 사용된 용어, "치료"는 상기 구강용 조성물을 이용하여 질환의 증세가 완화되거나 완치되는 모든 행위를 의미한다.As used herein, the term "prevention" refers to any activity that suppresses or delays a disease by using the composition for oral cavity. In addition, as used herein, the term "treatment" refers to all activities in which the symptoms of a disease are alleviated or cured by using the composition for oral cavity.
또한, 본 명세서에서 사용된 용어, "완화"는 상기와 같은 구강질환 증상 등이 줄어들거나 누그러지는 것을 의미하며, 개선, 예방, 치료 등을 포함하는 넓은 개념으로 이해될 수 있다.In addition, as used herein, the term "relieving" means reducing or mitigating the oral disease symptoms, etc., and can be understood as a broad concept including improvement, prevention, treatment, and the like.
또한, 본 명세서에서 사용된 용어, "개선"은 구강질환 등을 치료하여 증상을 원래의 상태에 가깝도록 회복시키는 것을 의미하는 넓은 개념으로 이해될 수 있다.In addition, the term "improvement" used herein may be understood as a broad concept meaning restoring symptoms to an original state by treating oral diseases and the like.
본 명세서에서 사용된 용어, "구취"는 이에 한정되는 것은 아니지만, 후천적인 전신질환에 의해서나 타액중의 단백질, 음식물 찌꺼기 등이 구강 내에서 미생물에 의해 분해되어 생성된 물질이 분해되어 악취를 유발하는 물질을 생성함으로써 발생할 수 있다. 구취를 유발하는 1차 원인인 구강 내 미생물에는 이에 한정되는 것은 아니지만, 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속, 악티노마이세스(Actinomyces) 속, 악티노바실러스(Actinobacillus) 속 등이 있을 수 있다.The term "halitosis" as used herein is not limited thereto, but is caused by acquired systemic diseases or by decomposition of proteins in saliva, food waste, etc. can occur by creating a substance that Oral microorganisms that are the primary cause of bad breath include, but are not limited to, Streptococcus genus, Porphyromonas genus, Actinomyces genus, Actinobacillus genus, etc. This can be.
본 명세서에서 사용된 용어, "치아 우식증"은 이에 한정되는 것은 아니지만 구강 내 박테리아에 의해 치아가 손상되어 충치가 생기는 것을 의미한다. 예를 들어, 치아 표면에 생성된 바이오필름인 플라크(plaque)가 원인일 수 있다. 상기 구강 내 박테리아는 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속 등일 수 있다.As used herein, the term "dental caries" means, but is not limited to, dental caries caused by damage to teeth by bacteria in the oral cavity. For example, plaque, which is a biofilm formed on the surface of a tooth, may be the cause. The bacteria in the oral cavity may be Streptococcus genus, Porphyromonas genus, and the like.
본 명세서에서 사용된 용어, "치은염" 및 "치주염"은, 이에 한정되는 것은 아니지만, 치은연하치태내에 존재하는 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속 등의 세균이 적절한 생육조건이 형성되었을 때 치은 부위의 연조직에 감염을 일으켜 치은염 또는 치주염의 치주질환으로 발전하여 잇몸의 염증을 일으키는 구강질환일 수 있다.As used herein, the terms "gingivitis" and "periodontitis" are, but are not limited to, bacteria present in subgingival plaque ( Streptococcus ), Porphyromonas ( Porphyromonas ), and the like are suitable growth conditions When formed, it may be an oral disease that infects the soft tissues of the gingival area, develops into periodontal disease of gingivitis or periodontitis, and causes inflammation of the gums.
본 명세서에서 사용된 용어, "구강 내 점막 궤양"은 구내염(stomatitis)이라고도 하며, 이에 한정되는 것은 아니지만 구강 내 세균, 바이러스, 곰팡이 등에 의한 감염으로 인해 구강 내 점막(혜, 잇몸, 입술, 볼 안쪽 등)에 염증이 생기는 질환을 의미하며 상기 세균은 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속 등의 세균일 수 있다.As used herein, the term "oral mucosal ulcer" is also referred to as stomatitis, but is not limited thereto, due to infection by bacteria, viruses, fungi, etc. Etc.) means an inflammatory disease, and the bacteria may be bacteria such as the genus Streptococcus and the genus Porphyromonas .
본 명세서에서 사용된 용어, "치근단 질환"은 이에 한정되는 것은 아니지만, 치아의 뿌리 끝을 의미하는 치근단에 염증이 발생한 것을 의미할 수 있다. 치근단 질환으로는 치근단 낭종, 치근단 농양, 치근단 골육종 등이 있으며, 이에 한정되는 것은 아니지만 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속 등의 세균에 의해서 발생할 수 있다.As used herein, the term "apical disease" may mean, but is not limited to, inflammation of the apical end of the tooth root. Apical diseases include apical cyst, apical abscess, apical osteosarcoma, etc., but are not limited thereto, and may be caused by bacteria such as Streptococcus genus and Porphyromonas genus.
본 명세서에서 사용된 용어, "시린이"는 이에 한정되는 것은 아니지만, 충치나 다른 병적인 원인과 별개로, 외부 자극에 대해 예리하고 일시적이거나 지속적인 통증이 나타나는 모든 현상을 의미한다. 상기 외부 자극은 보통 온도 자극을 의미하며, 대개 차가운 온도 자극에 증상을 호소하는데 뜨거운 온도에 통증이 나타나기도 한다. 이와 같은 온도 자극 외에도 치아의 건조, 외부 물질과의 접촉, 달거나 신 음식을 통한 삼투압 등의 자극에 의해서도 통증이 나타날 수 있다. 이는 치아 전체에 전반적으로 나타나기도 하며, 상악이나 하악, 또는 오른쪽이나 왼쪽 등 특정 부위에 한정되어 나타나기도 하고, 상아질 지각과민증(dentine hyperesthesia), 우식, 치수 염증과 동반하기도 한다.As used herein, the term "cold ear" refers to any phenomenon in which sharp, temporary or continuous pain is manifested in response to external stimuli, apart from tooth decay or other pathological causes, but is not limited thereto. The external stimulus usually means a temperature stimulus, and usually complains of symptoms in a cold temperature stimulus, but pain may appear in a hot temperature. In addition to these temperature stimuli, pain may also be caused by stimuli such as tooth drying, contact with external substances, and osmotic pressure through sweet or sour food. It may appear throughout the entire tooth, may be limited to a specific area such as the upper or lower jaw, or the right or left side, or may be accompanied by dentine hyperesthesia, caries, or pulp inflammation.
이러한 시린이 증상의 원인으로는 상아세관의 입구 노출을 고려할 수 있다.Exposure of the entrance of the dentinal tubules can be considered as the cause of these symptoms.
에나멜질 또는 시멘트질이 파괴되어 상아세관의 입구가 외부로 노출되면 상아세관의 세포돌기, 신경 및 상아질액에 의하여 자극이 치수 쪽으로 전달되어 통증을 느낄 수 있다.When the enamel or cementum is destroyed and the entrance of the dentinal tubule is exposed to the outside, stimulation is transmitted to the dental pulp by the cell protrusions, nerves, and dentin fluid of the dentinal tubule, so that pain can be felt.
본 발명의 발명자들은 카사바 추출물이 치아 표면 및/또는 상아세관 내에 잘 흡착될 수 있는 특성을 가져 시린이 증상의 예방 및 완화에 탁월한 효과가 있음을 확인함으로써 본 발명을 완성하였다.The inventors of the present invention have completed the present invention by confirming that the cassava extract has a property that can be well adsorbed on the tooth surface and/or within the dentinal tubules, so that it has an excellent effect on preventing and alleviating the symptoms of syringitis.
본 명세서에서 사용된 용어, "추출물"은 카사바의 추출 처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.As used herein, the term "extract" refers to an extract obtained by extraction of cassava, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof, It includes the extract itself and extracts of all formulations that can be formed using the extract.
본 발명의 상기 카사바 추출물은, 상기 카사바의 천연, 잡종 또는 변종 식물의 다양한 기관으로부터 추출될 수 있고, 예를 들어 카사바의 종자(씨앗), 뿌리, 지상부, 줄기, 잎, 꽃, 열매의 몸통, 열매의 껍질뿐만 아니라 식물 조직 배양물로부터도 추출이 가능하다.The cassava extract of the present invention can be extracted from various organs of natural, hybrid or mutant plants of cassava, for example, seeds (seeds), roots, aerial parts, stems, leaves, flowers, fruit bodies of cassava, It can be extracted not only from the skin of the fruit but also from plant tissue culture.
본 발명의 상기 카사바 추출물은 바람직하게는 카사바의 종자 또는 지상부의 추출물일 수 있으며, 더욱 바람직하게는 지상부 추출물일 수 있다. 본 발명에서 상기 지상부는 카사바의 지상부라면 어느 부위에 한정되는 것은 아니나, 바람직하게는 지상부 전체일 수 있다.The cassava extract of the present invention may preferably be an extract of seeds or aerial parts of cassava, more preferably an extract of aerial parts. In the present invention, the above-ground portion is not limited to any part of the above-ground portion of cassava, but may preferably be the entire above-ground portion.
본 발명의 상기 카사바 추출물에 있어서, 상기 카사바를 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 용매 추출법, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2 종 이상의 방법을 병용하여 수행될 수 있고, 바람직하게는 용매 추출법을 이용하여 수행할 수 있다.In the cassava extract of the present invention, the method for extracting the cassava is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include solvent extraction, hot water extraction, ultrasonic extraction, filtration, reflux extraction, and the like, which may be performed alone or in combination of two or more methods, preferably solvent extraction. This can be done using an extraction method.
본 발명에서 상기 카사바를 추출하는 데에 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물, 증류수, 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올, 아세톤, 에테르, 벤젠, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, n-헥산, 염산, 초산, 포름산, 구연산, 디에틸에테르 및 사이클로헥산으로 이루어진 군 중에서 선택되는 하나 이상의 용매 등을 들 수 있으며, 알코올을 용매로 사용하는 경우에는 바람직하게는 C1 내지 C4의 알코올(메탄올, 에탄올, 프로판올, 부탄올)을 사용할 수 있다. 본 발명에서 상기 카사바의 추출 용매로 보다 바람직하게는 물 또는 증류수를 사용할 수 있다.In the present invention, the type of extraction solvent used to extract the cassava is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent include water, distilled water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, citric acid, di and one or more solvents selected from the group consisting of ethyl ether and cyclohexane, and the like. When alcohol is used as the solvent, preferably, C 1 to C 4 alcohols (methanol, ethanol, propanol, butanol) can be used. there is. In the present invention, more preferably, water or distilled water can be used as the cassava extraction solvent.
본 발명의 구강용 조성물은 스트렙토코커스(streptococcus) 속 또는 포피로모나스(Porphyromonas) 속, 더욱 상세하게는 스트렙토코커스 뮤탄스(streptococcus mutans), 스트렙토코커스 상귀스(streptococcus sanguis), 스트렙토코커스 상귀니스(Streptococcus sanguinis), 스트렙토코커스 살리바리우스 종 써모필스(Streptococcus salivarius subsp. thermophils), 및 포피로모나스 진지발리스(Porphyromonas gingivalis)로 이루어진 군에서 선택된 하나 이상의 세균에 항균 효과가 탁월하여 구강질환의 예방 및 치료에 우수한 효과가 있음을 확인하였다.The oral composition of the present invention is Streptococcus genus or Porphyromonas genus ( Porphyromonas ) genus, more specifically, Streptococcus mutans ( streptococcus mutans ), Streptococcus sanguis ( streptococcus sanguis ), Streptococcus sanguinis ( Streptococcus sanguinis ), Streptococcus salivarius species Thermophils ( Streptococcus salivarius subsp. thermophils ), and Porphyromonas gingivalis ( Porphyromonas gingivalis ), it was confirmed that the antibacterial effect was excellent on one or more bacteria selected from the group consisting of, and thus, there was an excellent effect in preventing and treating oral diseases.
더 바람직하게는 본 발명의 구강용 조성물은 스트렙토코커스 뮤탄스(streptococcus mutans) 또는 포피로모나스 진지발리스(Porphyromonas gingivalis) 세균에 항균 효과가 탁월할 수 있다.More preferably, the oral composition of the present invention may have an excellent antibacterial effect against Streptococcus mutans or Porphyromonas gingivalis bacteria.
본 발명에 있어서, 상기 카사바(cassava) 추출물은 조성물 총 중량 대비 1 내지 10 중량% 일 수 있으며, 바람직하게는 조성물 총 중량 대비 3 내지 7 중량% 일 수 있고, 더욱 바람직하게는 조성물 총 중량 대비 4 내지 6 중량% 일 수 있다. 상기 카사바(cassava) 추출물이 조성물 총 중량 대비 1 중량% 미만인 경우 구강질환에 효과가 미비할 수 있으며, 10 중량% 초과인 경우 양치 시 맛 등의 사용감이 좋지 않아 바람직하지 않다.In the present invention, the cassava extract may be 1 to 10% by weight based on the total weight of the composition, preferably 3 to 7% by weight based on the total weight of the composition, more preferably 4% by weight based on the total weight of the composition to 6% by weight. If the cassava extract is less than 1% by weight relative to the total weight of the composition, the effect on oral diseases may be insufficient, and if it is more than 10% by weight, it is not preferable because the feeling of use such as taste is not good when brushing teeth.
본 발명의 구강용 조성물은 상기 카사바 추출물 이외에, 그 제형 및 사용 목적에 따라 통상적으로 성분들로서, 습윤제, 연마제, 약효제, 감미제, pH조정제, 방부제, 결합제, 향료, 기포제 등을 더 포함할 수 있다. In addition to the cassava extract, the oral composition of the present invention may further include a wetting agent, an abrasive, a medicinal agent, a sweetening agent, a pH adjusting agent, a preservative, a binder, a flavoring agent, a foaming agent, etc. .
습윤제로는 농글리세린, 글리세린, 소르비톨수용액, 비결정성 소르비톨수용액, 폴리에틸렌글리콜류 및 프로필렌글리콜로 이루어진 군중에서 단독 또는 혼합하여 사용하며, 그 사용량은 구강용 조성물 전체 중량 대비 1 내지 70중량% 포함될 수 있다.The humectant is used alone or in combination in the group consisting of concentrated glycerin, glycerin, sorbitol aqueous solution, amorphous sorbitol aqueous solution, polyethylene glycols and propylene glycol, and the amount used may be 1 to 70% by weight relative to the total weight of the oral composition. .
연마제로는 침강실리카, 실리카겔, 지르코늄실리케이트, 인산일수소칼슘, 무수인산일수소칼슘, 함수알루미나, 경질탄산칼슘, 중질탄산칼슘, 칼슘피로인산염, 불용성메타인산염 및 알루미늄실리케이트로 이루어진 군중에서 선택된 1종 등을 사용할 수 있다. 이러한 연마제의 사용량은 일반적으로 구강용 조성물 총 중량 대비 1 내지 60 중량%일 수 있다. 또한 소량 사용되는 첨가제로는 통상 사용되는 성분들로서 감미제, pH 조정제, 방부제, 착색제, 결합제가 포함될 수 있다. The abrasive is one selected from the group consisting of precipitated silica, silica gel, zirconium silicate, calcium monohydrogen phosphate, anhydrous calcium monohydrogen phosphate, hydrous alumina, light calcium carbonate, heavy calcium carbonate, calcium pyrophosphate, insoluble metaphosphate and aluminum silicate. etc. can be used. The amount of the abrasive used may generally be 1 to 60% by weight based on the total weight of the oral composition. In addition, additives used in small amounts may include sweeteners, pH adjusters, preservatives, colorants, and binders as commonly used components.
약효제는 불화나트륨, 일불소인산나트륨, 불화나트륨, 불화주석, 클로로헥시딘, 알란토인 클로로히드록시알루미네이트, 아미노카프론산, 염화아연, 염산피리독신, 초산토코페롤, 효소류 등을 단독 또는 2종 이상 혼합하여 사용할 수 있다. Sodium fluoride, sodium monofluorophosphate, sodium fluoride, tin fluoride, chlorhexidine, allantoin chlorohydroxyaluminate, aminocaproic acid, zinc chloride, pyridoxine hydrochloride, tocopherol acetate, enzymes, etc. alone or in combination It can be used by mixing more than one.
결합제로는 카르복시메틸셀룰로오스나트륨, 카보머, 카라기난, 잔탄검, 알지네이트류 등을 사용할 수 있고, 기포제로서 알킬황산나트륨, 라우릴황산나트륨, 자당지방산에스테르, 소르비탄지방산에스테르 등의 음이온 및 비이온 계면 활성제를 단독 또는 2종 이상을 혼합하여 사용할 수 있다. 이러한 결합제의 사용량은 일반적으로 구강용 조성물 총 중량 대비 0.1 내지 3 중량%이며, 바람직하게 0.5 내지 2 중량%일 수 있다.Sodium carboxymethylcellulose, carbomer, carrageenan, xanthan gum, alginate, etc. can be used as a binder, and anionic and nonionic surfactants such as sodium alkyl sulfate, sodium lauryl sulfate, sucrose fatty acid ester, sorbitan fatty acid ester, etc. can be used as a foaming agent. It can be used individually or in mixture of 2 or more types. The amount of the binder used is generally 0.1 to 3% by weight, preferably 0.5 to 2% by weight, based on the total weight of the oral composition.
감미제로는 사카린, 자일리톨, 에리스리톨, 아스파탐 등을 사용할 수 있으며, 이러한 감미제의 사용량은 일반적으로 구강용 조성물 총 중량 대비 0.05 내지 2 중량%일 수 있다.Saccharin, xylitol, erythritol, aspartame, etc. may be used as the sweetener, and the amount of the sweetener used may be 0.05 to 2% by weight based on the total weight of the oral composition.
pH조정제로는 인산나트륨, 인산이나트륨, 구연산, 트리에탄올아민 등을 사용할 수 있다.As the pH adjusting agent, sodium phosphate, disodium phosphate, citric acid, triethanolamine, and the like can be used.
방부제로는 안식향산, 메틸파라벤, 프로필파라벤, 안식향산나트륨 등을 사용할 수 있다. 향료로는 페퍼민트 오일, 스피아민트 오일, 멘톨 등을 혼합하여 사용하기도 하며, 기타 첨가제로서 덱스타라나제 등의 효소류를 사용 할 수도 있다.Benzoic acid, methyl paraben, propyl paraben, sodium benzoate, etc. may be used as preservatives. Peppermint oil, spearmint oil, menthol, etc. may be mixed and used as flavoring agents, and enzymes such as dextranase may be used as other additives.
기포제로는 음이온성 계면활성제인 라우릴황산나트륨, 비이온성 계면활성제인 폴리옥시에틸렌폴리옥시프로필렌의 공중합체(폴록사머), 폴리옥시에틸렌경화피마자유, 폴리옥시에틸렌솔비탄 지방산에스테르 등이 사용될 수 있다. 이러한 기포제의 사용량은 일반적으로 구강용 조성물 총 중량 대비 0.5 내지 5 중량%이며, 바람직하게 0.5 내지 3.5 중량%일 수 있다.As the foaming agent, sodium lauryl sulfate as an anionic surfactant, polyoxyethylene polyoxypropylene copolymer (poloxamer) as a nonionic surfactant, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid ester, etc. may be used. . The amount of these foaming agents is generally 0.5 to 5% by weight, preferably 0.5 to 3.5% by weight, based on the total weight of the oral composition.
그밖에 잔량의 물을 포함한다.In addition, the residual amount of water is included.
본 발명의 또 다른 구현예에 따르면, 상기 조성물을 포함하는 구강용 제품을 제공한다.According to another embodiment of the present invention, an oral product comprising the composition is provided.
카사바 추출물을 유효성분으로 하는 본 발명에 따른 구강용 조성물은 일반적으로 구강 건강을 위해 제조, 시판되는 제품들에 모두 포함될 수 있는 구강용 조성물로서, 적용되는 구강용 제품에는 제한이 없다. 예를 들어, 상기 구강용 제품으로는 치약, 구강 스프레이, 구강 세정제, 구강용 연고, 구강 청정제, 가글링 제품, 껌 등을 포함하나 이에 한정되지 않는다. 본 발명의 구강용 제품은 액상, 고상, 현탁액, 젤상, 에어로졸 형태일 수 있으나, 이에 한정되는 것은 아니다.The oral composition according to the present invention containing cassava extract as an active ingredient is a composition for oral use that can be included in all commercially available products generally manufactured for oral health, and the applied oral products are not limited. For example, the oral product includes, but is not limited to, toothpaste, oral spray, mouthwash, oral ointment, mouthwash, gargling product, chewing gum, and the like. The oral product of the present invention may be in the form of a liquid, solid, suspension, gel, or aerosol, but is not limited thereto.
본 발명의 카사바 추출물을 포함하는 구강용 조성물은 구강질환 예방 또는 치료 효과가 우수하다.Oral composition containing the cassava extract of the present invention is excellent in preventing or treating oral diseases.
또한, 본 발명의 조성물은 천연물 유래의 물질이어서 독성이 없으며, 인체에 적용하여도 부작용을 유발하지 않아 활용도가 높다.In addition, the composition of the present invention is not toxic because it is a material derived from natural products, and it does not cause side effects even when applied to the human body, so its utilization is high.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, examples and the like will be described in detail to aid understanding of the present invention. However, the embodiments according to the present invention can be modified in many different forms, and the scope of the present invention should not be construed as being limited to the following examples. Embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
재료 준비material preparation
카사바 추출물의 제조Manufacture of Cassava Extract
카사바 지상부 약 100g을 분쇄한 후 200mL의 증류수를 가하여 실온에서 1회 추출한 후 여과하여 물 추출물을 얻었다.After crushing about 100 g of the aerial parts of cassava, 200 mL of distilled water was added to extract once at room temperature, followed by filtration to obtain a water extract.
<< 실험예Experimental example 1> 1>
시린이sirin 현상 억제 정도 비교 Comparison of degree of suppression
시린이 억제정도를 비교하기 위하여, 우선 치약을 제조하기 위해 하기 표 1과 같이 일반적으로 사용될 수 있는 카르복시메틸셀룰로오스나트륨, 라우릴황산나트륨, 글리세린(농글리세린(98%)), 소르비톨 수용액(70%), 실리카류(침강 실리카), 잔탄검, 불화나트륨, 향료, 사카린, 구연산, 트리에탄올아민(Triethanol amine(TEA)) 등을 사용하여 대조군 치약을 만들었고, 여기에 카사바 추출물이 5 중량% 함유된 실험군 치약을 제조하였다.In order to compare the degree of inhibition of syrin, first, sodium carboxymethylcellulose, sodium lauryl sulfate, glycerin (concentrated glycerin (98%)), sorbitol aqueous solution (70%), which can be generally used as shown in Table 1 below, to prepare toothpaste , Silicas (precipitated silica), xanthan gum, sodium fluoride, fragrance, saccharin, citric acid, triethanolamine (TEA), etc. were used to make a control toothpaste, and an experimental group toothpaste containing 5% by weight of cassava extract was manufactured.
상기에서 제조한 조성물들의 시린이 현상 억제 정도를 비교 측정하였다. 즉, 지각과민치아를 가진 사람으로 이 실험에 참여하기를 동의한 지원자 40명을 연구대상으로 하였으며, 총 연구대상 치아는 80개이다. 또한, 지원자 중 남자가 20명, 여자가 20명이었고, 연령은 20세 내지 50세였다. 연구 대상자들은 치약 내용물을 알지 못하도록 하였고, 총 시험기간은 2주로 하였다. The degree of suppression of shirin of the compositions prepared above was compared and measured. That is, 40 volunteers who agreed to participate in this experiment as people with hypersensitive teeth were studied, and the total number of teeth for the study was 80. In addition, 20 men and 20 women were among the volunteers, and their ages ranged from 20 to 50 years. The subjects of the study were unaware of the contents of the toothpaste, and the total test period was 2 weeks.
온도자극을 가한 후 환자의 반응을 측정하는 방법으로 시험을 실시하였다. 시험을 실시하기 전에 미리 각 지원자의 지각과민 치아의 과민부위를 체크하였고, 치아의 시린부위에 약 5℃의 차가운 물을 스포이드로 떨어뜨려 평점을 한 후 2주간 각각의 조성물을 1일 3회 사용하게 하고, 2주가 지나 다시 약 5℃의 차가운 물을 스포이드로 떨어뜨려 평점을 하였다. 자극 후 환자의 반응 평점 기준은 다음과 같이 설정하였다. (0점: 아무런 불편감이 없다., 1점: 약간 불편하거나 시리다., 3점: 아프다.). 통계처리는 실험실시 전과 2주 후의 자극 점수를 paired student-t test로 검정하였다.The test was conducted by measuring the patient's response after applying the temperature stimulus. Before the test, the hypersensitive area of each volunteer's hypersensitive teeth was checked in advance, and cold water of about 5 ° C was dropped on the cold part of the tooth with a dropper, and then each composition was used three times a day for 2 weeks. After 2 weeks, cold water at about 5 ° C. was dropped again with a dropper and evaluated. The patient's response rating criteria after stimulation were set as follows. (0 points: no discomfort, 1 point: slightly uncomfortable or cold, 3 points: painful). For statistical processing, stimulation scores before and 2 weeks after the laboratory test were tested by paired student-t test.
2주 후의 온도자극에 대한 반응점수는 다음 표 2와 같다.The response scores for the temperature stimulation after 2 weeks are shown in Table 2 below.
<< 실험예Experimental example 2> 2>
구취 제거 효과 실험Bad breath removal effect experiment
구취제거 정도를 비교하기 위하여 상기 표 1과 같은 구성으로 대조군 및 실험군 치약을 제조하였다.In order to compare the degree of bad breath removal, toothpastes for the control group and the experimental group were prepared with the configuration shown in Table 1 above.
치아우식증이 없는 남녀 50명을 선정하여 대상 음료에 대하여 교차 반복 실험(Cross-over test)을 실시하였다. 시판하는 마늘분을 물에 분산시켜 24시간 방치한 후 희석하여 할리미터(Halimeter) 측정값이 700ppb 이상이 되도록 하여, 상기 희석액을 구취 유발원으로 사용하였다. 마늘분 희석액 15ml로 30초간 가글을 한 후 1분 뒤에 할리미터로 구취정도를 측정한 후, 대조군, 실험군 치약을 사용하여 30초~1분간 양치질하였다. 양치질 수 1분, 5분, 30분 경과 후 할리미터로 구취정도를 측정하여 구취억제의 지속여부를 측정하였다. 그 결과는 하기 표 3과 같다.Fifty men and women without dental caries were selected and a cross-over test was conducted on the target beverage. Commercially available garlic powder was dispersed in water and allowed to stand for 24 hours, then diluted so that the Halimeter measurement value was 700 ppb or more, and the diluted solution was used as a source of bad breath. After gargling with 15 ml of diluted garlic powder for 30 seconds, after 1 minute, the degree of bad breath was measured with a halimeter, and then brushed teeth for 30 seconds to 1 minute using toothpaste from the control group and the experimental group. After 1 minute, 5 minutes, and 30 minutes of brushing the teeth, the degree of bad breath was measured with a halimeter to determine whether or not the bad breath suppression continued. The results are shown in Table 3 below.
<< 실험예Experimental example 3> 3>
항균 효과 실험Antibacterial effect test
치아우식과 치주질환 대표유발 세균인, 그람양성균 스트렙토코커스 뮤탄스(Streptococcus mutans)와 그람음성균인 포피로모나스 진지발리스(Porphyromonas gingivalis)를 이용하여 균주를 억제하는 효과가 있는지 페이퍼 디스크 검사법을 사용하여 항균력 테스트를 실시하였다. 상기 각 세균들은 하기 표 4의 최적 배양조건에서 활성을 키운 후, 각 균의 최적배지에서 4~6시간 정도 배양하여 배양액의 탁도를 Macfarland turbidity No. 0.5 (1.5x108)가 되도록 맞춘 후, 0.1ml를 골고루 도말하였다. 멸균한 페이퍼 디스크(Whatman no.5 paper, 8mm diameter)에 카사바 추출물을 10mg/disc 농도로 접종하여 1시간 동안 흡수건조시킨 뒤 사용하였다. 상기의 각 세균의 최적온도에서 24-48시간 배양 후 생육저지환의 크기(직경 mm)를 측정하였다.By using the gram-positive bacterium Streptococcus mutans and the gram-negative bacterium Porphyromonas gingivalis , which are representative bacteria that cause dental caries and periodontal disease, the paper disk test method is used to determine whether there is an effect of inhibiting the strain. An antimicrobial activity test was conducted. After cultivating each of the bacteria under the optimal culture conditions in Table 4 below, the turbidity of the culture solution was determined by culturing in the optimal medium for each bacteria for about 4 to 6 hours. After adjusting to be 0.5 (1.5x10 8 ), 0.1 ml was spread evenly. A sterilized paper disk (Whatman no.5 paper, 8 mm diameter) was inoculated with cassava extract at a concentration of 10 mg/disc, and dried by absorption for 1 hour before use. After culturing for 24-48 hours at the optimal temperature of each of the above bacteria, the size (diameter mm) of the growth arrest ring was measured.
그 결과는 하기 표 5에 나타낸 것과 같다.The results are as shown in Table 5 below.
상기에 나타낸 바와 같이 본 발명에 따른 조성물은 구취, 시린이, 치아 우식증, 치은염, 치주염, 구강 내 점막 궤양 및 치근단 질환 등의 구강 질환에 탁월한 효과가 있는 것으로 확인할 수 있었다.As described above, it was confirmed that the composition according to the present invention has an excellent effect on oral diseases such as halitosis, toothache, dental caries, gingivitis, periodontitis, oral mucosal ulcers and apical diseases.
Claims (14)
상기 카사바 추출물은 카사바의 지상부를 추출하여 수득한 것이며,
구취, 시린이, 및 치아 우식증으로 이루어진 군에서 선택되는 1 종 이상의 구강질환 예방 또는 치료용 구강용 조성물.Contains cassava extract as an active ingredient,
The cassava extract is obtained by extracting the aerial part of cassava,
An oral composition for preventing or treating one or more oral diseases selected from the group consisting of halitosis, ache, and dental caries.
상기 카사바(cassava) 추출물은 카사바에 물, 증류수, 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올, 아세톤, 에테르, 벤젠, 클로로포름, 에틸아세테이트, 메틸렌클로라이드, n-헥산, 염산, 초산, 포름산, 구연산, 디에틸에테르 및 사이클로헥산으로 이루어진 군 중에서 선택되는 하나 이상의 용매를 첨가하여 추출한 용매 추출물인 것을 특징으로 하는 구강용 조성물.According to claim 1,
The cassava extract is obtained by adding water, distilled water, methanol, ethanol, propanol, isopropanol, butanol, acetone, ether, benzene, chloroform, ethyl acetate, methylene chloride, n-hexane, hydrochloric acid, acetic acid, formic acid, citric acid, distilled water to cassava. An oral composition characterized in that it is a solvent extract extracted by adding at least one solvent selected from the group consisting of ethyl ether and cyclohexane.
상기 카사바(cassava) 추출물은 물 또는 증류수 추출물인 것을 특징으로 하는 구강용 조성물.According to claim 1,
The oral composition, characterized in that the cassava extract is a water or distilled water extract.
상기 카사바(cassava) 추출물은 조성물 총 중량 대비 1 내지 10 중량%인 것을 특징으로 하는 구강용 조성물.According to claim 1,
The cassava extract is an oral composition, characterized in that 1 to 10% by weight relative to the total weight of the composition.
상기 조성물은 스트렙토코커스(streptococcus) 속 또는 포피로모나스(Porphyromonas) 속에 항균 효과가 있는 것을 특징으로 하는 구강용 조성물.According to claim 1,
The composition is an oral composition, characterized in that there is an antibacterial effect in the genus Streptococcus or Porphyromonas .
상기 스트렙토코커스(streptococcus) 속 또는 포피로모나스(Porphyromonas) 속은 스트렙토코커스 뮤탄스(streptococcus mutans), 스트렙토코커스 상귀스(streptococcus sanguis), 스트렙토코커스 상귀니스(Streptococcus sanguinis), 스트렙토코커스 살리바리우스 종 써모필스(Streptococcus salivarius subsp. thermophils), 및 포피로모나스 진지발리스(Porphyromonas gingivalis)로 이루어진 군에서 선택된 하나 이상인 것을 특징으로 하는 구강용 조성물.According to claim 9,
The Streptococcus genus or Porphyromonas genus includes Streptococcus mutans , Streptococcus sanguis , Streptococcus sanguinis , Streptococcus salivarius species Thermophils ( Streptococcus salivarius subsp. thermophils ), and Porphyromonas gingivalis ( Porphyromonas gingivalis ) Oral composition, characterized in that at least one selected from the group consisting of.
상기 스트렙토코커스(streptococcus) 속 또는 포피로모나스(Porphyromonas) 속은 스트렙토코커스 뮤탄스(streptococcus mutans) 또는 포피로모나스 진지발리스(Porphyromonas gingivalis)인 것을 특징으로 하는 구강용 조성물.According to claim 9,
The Streptococcus ( streptococcus ) or Porphyromonas ( Porphyromonas ) genus Streptococcus mutans ( streptococcus mutans ) or Porphyromonas gingivalis ( Porphyromonas gingivalis ) Oral composition, characterized in that.
상기 카사바(cassava) 추출물은 치아 표면 또는 상아세관 내에 흡착되는 것을 특징으로 하는 구강용 조성물.According to claim 1,
Oral composition, characterized in that the cassava extract is adsorbed on the tooth surface or in the dentinal tubules.
상기 구강용 제품은 치약, 가글링 제품, 껌, 구강 스프레이, 구강용 연고, 구강 세정제 및 구강 청정제로 이루어지는 군 중에서 선택되는 것을 특징으로 하는 구강용 제품.According to claim 13,
The oral product, characterized in that selected from the group consisting of toothpaste, gargling products, chewing gum, oral spray, oral ointment, mouthwash and mouthwash.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150136505A KR102509579B1 (en) | 2015-09-25 | 2015-09-25 | Oral composition comprising cassava extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020150136505A KR102509579B1 (en) | 2015-09-25 | 2015-09-25 | Oral composition comprising cassava extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170037230A KR20170037230A (en) | 2017-04-04 |
KR102509579B1 true KR102509579B1 (en) | 2023-03-10 |
Family
ID=58588397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150136505A KR102509579B1 (en) | 2015-09-25 | 2015-09-25 | Oral composition comprising cassava extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102509579B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108721369A (en) * | 2018-06-28 | 2018-11-02 | 广西浙缘农业科技有限公司 | A kind of extracting method of cassava bark extract |
CN110179714A (en) * | 2019-06-27 | 2019-08-30 | 中国热带农业科学院热带作物品种资源研究所 | A kind of production method of cassava health-care face mask |
KR20240109466A (en) * | 2023-01-04 | 2024-07-11 | 주식회사 엘지생활건강 | Oral material comprising chicory dietary fiber or cassava starch |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007326808A (en) * | 2006-06-07 | 2007-12-20 | Matsutani Chem Ind Ltd | Edible film for oral hygiene |
JP2015024982A (en) * | 2013-07-29 | 2015-02-05 | 上野製薬株式会社 | Advanced glycation end products formation inhibitor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140031512A (en) | 2012-09-03 | 2014-03-13 | 창원대학교 산학협력단 | Composition for treating oral disease and inhibiting halitosis comprising the extract of schizandra chinensis |
-
2015
- 2015-09-25 KR KR1020150136505A patent/KR102509579B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007326808A (en) * | 2006-06-07 | 2007-12-20 | Matsutani Chem Ind Ltd | Edible film for oral hygiene |
JP2015024982A (en) * | 2013-07-29 | 2015-02-05 | 上野製薬株式会社 | Advanced glycation end products formation inhibitor |
Non-Patent Citations (1)
Title |
---|
Journal of Ethnopharmacology 119 (2008) 6~11 |
Also Published As
Publication number | Publication date |
---|---|
KR20170037230A (en) | 2017-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102509579B1 (en) | Oral composition comprising cassava extract | |
KR20180081032A (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
KR102597684B1 (en) | Oral composition comprising amaranth extract | |
KR101881636B1 (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
KR20170103476A (en) | Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract | |
JP2003012483A (en) | Composition for oral cavity application | |
KR102597685B1 (en) | Oral composition comprising parsley extract | |
KR102379228B1 (en) | Oral composition comprising chives extract | |
KR20160061852A (en) | Oral composition containing both metal chelating agent and isopropylmethylphenol | |
KR101021787B1 (en) | Oral composition effective for removing gum disease and bad breath | |
KR20170037231A (en) | Oral composition comprising purslane extract | |
KR20170051006A (en) | Oral composition containing both isopropylmethylphenol and oral tissue astringent | |
KR102682447B1 (en) | Oral composition comprising hinokitiol | |
KR101344803B1 (en) | Oral care composition comprising extract of machilus thunbergii and sequestering agent | |
KR20020082308A (en) | Composition for the mouth containing extraction of Euonymus alatus Sieb | |
KR0138248B1 (en) | Oral Hygiene Composition Containing Plant Extracts | |
KR20170103482A (en) | Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract | |
KR20170103494A (en) | Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract | |
KR20110128961A (en) | Oral composition containing green tea extract | |
KR101818211B1 (en) | Composition for prevention or treatment of oral disease comprising Arctill fructus Extract | |
KR20170120411A (en) | Composition for prevention or treatment of oral disease comprising Scopoletin | |
KR102562829B1 (en) | Composition for prevention or treatment of oral disease comprising Alpinia officinarum Extract | |
KR102562830B1 (en) | Composition for prevention or treatment of oral disease comprising Kochiae Fructus Extract | |
KR20170142975A (en) | Composition for prevention or treatment of oral disease comprising Leonurus sibiricus extract | |
KR20170103517A (en) | Composition for prevention or treatment of oral disease comprising Prunus yedoensis Matsumura extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20150925 |
|
PG1501 | Laying open of application | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200918 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20150925 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20221020 Patent event code: PE09021S01D |
|
E701 | Decision to grant or registration of patent right | ||
PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20230307 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20230308 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20230308 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration |